hotspot -WSS

hotspot

author：hotspot 2025-09-29 01:06:27 - browse：24947

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

entertainment

WSS

UHS says company favors patients whose insurance pays more

Medicare has a new plan to address drug shortages

FDA approves RSV monoclonal antibody for infants, toddlers

Google and Epic fight stronger regulation of AI in health care

At Orexo, a ‘turning point’ for everything but digital health

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

knowledge

hotspot

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Hollywood unions extend contract negotiations for actors

How dance can help nurses traumatized by Covid

Jerome Adams on the need for new antivirals for Covid

UHS says company favors patients whose insurance pays more

New air purifier tech could be key to improving indoor air quality

Democrats decry new health bill for going easy on private equity

Virginia high school admissions case could be legal follow

Dems pitch expanding Medicare power to negotiate drug prices

entertainment

WHO calls for emergency meeting on new China virus, as cases spread

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

As digital health tech proliferates, a new institute aims to cut through hype

Dems pitch expanding Medicare power to negotiate drug prices

Medicare to cover more brain scans for Alzheimer’s patients

What to watch for from Zogenix and Amicus clinical trials

focus

entertainment

hotspot

focus